Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
92% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ISR: No Debt )
ISR' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ISR's Equity to Asset is ranked higher than
96% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISR: 0.91 )
ISR' s 10-Year Equity to Asset Range
Min: -1.18   Max: 0.91
Current: 0.91

-1.18
0.91
Interest Coverage No Debt
ISR's Interest Coverage is ranked higher than
90% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. ISR: No Debt )
ISR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 31.55
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -89.88
ISR's Operating margin (%) is ranked higher than
51% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. ISR: -89.88 )
ISR' s 10-Year Operating margin (%) Range
Min: -360.83   Max: -10.59
Current: -89.88

-360.83
-10.59
Net-margin (%) -85.24
ISR's Net-margin (%) is ranked higher than
53% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. ISR: -85.24 )
ISR' s 10-Year Net-margin (%) Range
Min: -412.14   Max: -6.45
Current: -85.24

-412.14
-6.45
ROE (%) -71.88
ISR's ROE (%) is ranked higher than
53% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ISR: -71.88 )
ISR' s 10-Year ROE (%) Range
Min: -284.75   Max: -42.28
Current: -71.88

-284.75
-42.28
ROA (%) -54.67
ISR's ROA (%) is ranked higher than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ISR: -54.67 )
ISR' s 10-Year ROA (%) Range
Min: -6600   Max: 182500
Current: -54.67

-6600
182500
ROC (Joel Greenblatt) (%) -167.02
ISR's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. ISR: -167.02 )
ISR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -438.19   Max: -44.31
Current: -167.02

-438.19
-44.31
Revenue Growth (%) -17.30
ISR's Revenue Growth (%) is ranked higher than
54% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ISR: -17.30 )
ISR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 12.2
Current: -17.3

0
12.2
EBITDA Growth (%) -11.50
ISR's EBITDA Growth (%) is ranked higher than
58% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. ISR: -11.50 )
ISR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 205.5
Current: -11.5

0
205.5
EPS Growth (%) -15.10
ISR's EPS Growth (%) is ranked higher than
58% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ISR: -15.10 )
ISR' s 10-Year EPS Growth (%) Range
Min: -67.8   Max: 233.2
Current: -15.1

-67.8
233.2
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ISR Guru Trades in

ISR Guru Trades in

ISR Guru Trades in

Q1 2014

ISR Guru Trades in Q1 2014

Jeff Auxier 14,218 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ISR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.72
ISR's P/B is ranked higher than
57% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ISR: 5.72 )
ISR' s 10-Year P/B Range
Min: 0.31   Max: 55
Current: 5.72

0.31
55
P/S 20.23
ISR's P/S is ranked higher than
51% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. ISR: 20.23 )
ISR' s 10-Year P/S Range
Min: 0.56   Max: 285
Current: 20.23

0.56
285
EV-to-EBIT -27.83
ISR's EV-to-EBIT is ranked lower than
51% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. ISR: -27.83 )
ISR' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 16.8
Current: -27.83

0.2
16.8
Current Ratio 24.59
ISR's Current Ratio is ranked higher than
99% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. ISR: 24.59 )
ISR' s 10-Year Current Ratio Range
Min: 0.82   Max: 24.59
Current: 24.59

0.82
24.59
Quick Ratio 24.21
ISR's Quick Ratio is ranked higher than
99% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ISR: 24.21 )
ISR' s 10-Year Quick Ratio Range
Min: 0.68   Max: 24.21
Current: 24.21

0.68
24.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.74
ISR's Price/Net Cash is ranked higher than
94% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISR: 6.74 )
ISR' s 10-Year Price/Net Cash Range
Min: 1   Max: 157.5
Current: 6.74

1
157.5
Price/Net Current Asset Value 6.42
ISR's Price/Net Current Asset Value is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISR: 6.42 )
ISR' s 10-Year Price/Net Current Asset Value Range
Min: 0.8   Max: 125
Current: 6.42

0.8
125
Price/Tangible Book 5.71
ISR's Price/Tangible Book is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. ISR: 5.71 )
ISR' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 51.79
Current: 5.71

0.35
51.79
Price/Median PS Value 3.92
ISR's Price/Median PS Value is ranked higher than
51% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. ISR: 3.92 )
ISR' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 51
Current: 3.92

0.12
51
Earnings Yield (Greenblatt) 108.50
ISR's Earnings Yield (Greenblatt) is ranked higher than
96% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. ISR: 108.50 )
ISR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 497.6
Current: 108.5

5.9
497.6
Forward Rate of Return (Yacktman) -177.88
ISR's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. ISR: -177.88 )
ISR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: 6.1
Current: -177.88

-9.6
6.1

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay, Inc. was organized under Minnesota law in 1983, formerly known as Century Park Pictures Corporation On July 28, 2005, Century changed its name to IsoRay, Inc. The Company provides treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. In August 2009, IsoRay Medical obtained treatment for Proxcelan(tm) Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands. Brachytherapy seeds are small devices used in a radiation procedure. IsoRay markets the Proxcelan Cs-131 brachytherapy seed for the treatment of prostate cancer, ocular melanomas, and head and neck cancers, and intends to market Cs-131 for the treatment of other malignant disease, such as lung, in the near future. The Company competes with both public and private medical device, biotechnology and pharmaceutical companies. The disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material.
» More Articles for ISR

Headlines

Articles On GuruFocus.com
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
Top Biotechnology Stocks Jul 23 2014
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a... Jul 14 2014
Why IsoRay (ISR) Stock Is Spiking Today Jul 14 2014
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a... Jul 14 2014
IsoRay Announces Its Addition to the Russell Microcap Index Jun 30 2014
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 25 2014
Why IsoRay (ISR) Stock Is Surging Today Jun 24 2014
IsoRay announces Cesitrex cleared by FDA for internal radiation therapy Jun 24 2014
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer... Jun 24 2014
IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of... Jun 20 2014
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 27 2014
ISORAY, INC. Financials May 23 2014
ISORAY, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders May 16 2014
IsoRay reports Q3 EPS (5c), one estimate (3c) May 16 2014
IsoRay, Inc. Reports Third Quarter Results May 16 2014
ISORAY, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Why IsoRay (ISR) Stock Is Surging Today May 12 2014
IsoRay (ISR) Is Today's Dead Cat Bounce Stock May 12 2014
IsoRay announces Liquid Cesium-131 receives regulatory approval May 12 2014
IsoRay's Liquid Cesium-131 (Cesitrex(R)) Recieves Final Regulatory Approval for Use in GliaSite(R)... May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide